BridgeBio Pharma to discuss additional data from ATTRibute-CM as presented at ISA 2024 05.29.2024 at 5:30 PM EDT Click here for webcast Supporting Materials BBIO-Acoramidis (AG10) TTR- ISA 2024- Featured research in the ATTR-CM landscape 1.3 MB Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy: Insights from the acoramidis phase 3 study ATTRibute-CM 11.1 MB
Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy: Insights from the acoramidis phase 3 study ATTRibute-CM 11.1 MB